ISGIO 2023
Advertisement
While liver cancer is the third deadliest cancer in the world, there are still unmet needs regarding the disease.
Dr. Vatche G. Agopian provided an overview of the neoadjuvant systemic therapy options for HCC at ISGIO 2023.
While therapies such as anti-VEGF therapy have improved hepatocellular cancer care, do these approaches have a role in BTC?
The BCLC stratifies HCC into 5 stages based on lesion, performance status, vascular invasion, and extrahepatic spread.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.